ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C28H22F3N7O
CAS番号:
分子量:
529.52
UNSPSC Code:
12352200
NACRES:
NA.21
MDL number:
SMILES string
FC(F)(F)c1cc(cc(c1)NC(=O)c3cc(c(cc3)C)Nc4nc(ccn4)c5cnccc5)[n]2cnc(c2)C
InChI
1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChI key
HHZIURLSWUIHRB-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
Quality Level
関連するカテゴリー
Biochem/physiol Actions
Orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor
Nilotinib (AMN107) is an orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor that is 10-30-fold more potent than imatinib. Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukemia (CML). Nilotinib reduces midbrain Bcr-Abl autophosphorylation, amyloid-β levels, and neuronal loss, as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimer’s disease.
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 4 - STOT RE 1
target_organs
Liver,Kidney,gallbladder
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
SML3799-10MG: + SML3799-VAR: + SML3799-BULK: + SML3799-50MG:
jan
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Cancer Cell, 7(2), 129-141 (2005)
Livia La Barbera et al.
Progress in neurobiology, 202, 102031-102031 (2021-03-09)
What happens precociously to the brain destined to develop Alzheimer's Disease (AD) still remains to be elucidated and this is one reason why effective AD treatments are missing. Recent experimental and clinical studies indicate that the degeneration of the dopaminergic
Tomer Meirson et al.
Oncotarget, 9(31), 22158-22183 (2018-05-19)
Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)